Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
Nadine G. Rouphael, … , Michael C. Keefer, the HVTN 105 Protocol Team and the NIAID HIV Vaccine Trials Network
Nadine G. Rouphael, … , Michael C. Keefer, the HVTN 105 Protocol Team and the NIAID HIV Vaccine Trials Network
Published September 30, 2019
Citation Information: J Clin Invest. 2019;129(11):4769-4785. https://doi.org/10.1172/JCI128699.
View: Text | PDF
Clinical Research and Public Health AIDS/HIV Article has an altmetric score of 30

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial

  • Text
  • PDF
Abstract

BACKGROUND RV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans. Attempting to build upon RV144 immune responses, we conducted a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenicity of regimens substituting the DNA-HIV-PT123 (DNA) vaccine for ALVAC-HIV in different sequences or combinations with AIDSVAX B/E (protein).METHODS One hundred and four HIV-uninfected participants were randomized to 4 treatment groups (T1, T2, T3, and T4) and received intramuscular injections at 0, 1, 3, and 6 months (M): T1 received protein at M0 and M1 and DNA at M3 and M6; T2 received DNA at M0 and M1 and protein at M3 and M6; T3 received DNA at M0, M1, M3, and M6 with protein coadministered at M3 and M6; and T4 received protein and DNA coadministered at each vaccination visit.RESULTS All regimens were well tolerated. Antibodies binding to gp120 and V1V2 scaffold were observed in 95%–100% of participants in T3 and T4, two weeks after final vaccination at high magnitude. While IgG3 responses were highest in T3, a lower IgA/IgG ratio was observed in T4. Binding antibodies persisted at 12 months in 35%–100% of participants. Antibody-dependent cell-mediated cytotoxicity and tier 1 neutralizing-antibody responses had higher response rates for T3 and T4, respectively. CD4+ T cell responses were detectable in all treatment groups (32%–64%) without appreciable CD8+ T cell responses.CONCLUSION The DNA/protein combination regimens induced high-magnitude and long-lasting HIV V1V2–binding antibody responses, and early coadministration of the 2 vaccines led to a more rapid induction of these potentially protective responses.TRIAL REGISTRATION ClinicalTrials.gov NCT02207920.FUNDING National Institute of Allergy and Infectious Diseases (NIAID) grants UM1 AI068614, UM1 AI068635, UM1 AI068618, UM1 AI069511, UM1 AI069470, UM1 AI069534, P30 AI450008, UM1 AI069439, UM1 AI069481, and UM1 AI069496; the National Center for Advancing Translational Sciences, NIH (grant UL1TR001873); and the Bill & Melinda Gates Foundation (grant OPP52845).

Authors

Nadine G. Rouphael, Cecilia Morgan, Shuying S. Li, Ryan Jensen, Brittany Sanchez, Shelly Karuna, Edith Swann, Magdalena E. Sobieszczyk, Ian Frank, Gregory J. Wilson, Hong-Van Tieu, Janine Maenza, Aliza Norwood, James Kobie, Faruk Sinangil, Giuseppe Pantaleo, Song Ding, M. Juliana McElrath, Stephen C. De Rosa, David C. Montefiori, Guido Ferrari, Georgia D. Tomaras, Michael C. Keefer, the HVTN 105 Protocol Team and the NIAID HIV Vaccine Trials Network

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 Total
Citations: 1 7 3 1 6 8 1 27
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (27)

Title and authors Publication Year
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
Moodie Z, Li SS, Giorgi EE, Williams LD, Dintwe O, Carpp LN, Chen S, Seaton KE, Sawant SS, Zhang L, Heptinstall J, Liu S, Grunenberg N, Tomaka F, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Ake JA, Vasan S, Pantaleo G, Frank I, Baden LR, Goepfert PA, Keefer M, Chirenje M, Hosseinipour MC, Mngadi K, Laher F, Garrett N, Bekker LG, De Rosa S, Andersen-Nissen E, Kublin JG, Lu S, Gilbert PB, Gray GE, Corey L, McElrath MJ, Tomaras GD
Emerging Microbes & Infections 2025
Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention
Tarrés-Freixas F, Clotet B, Carrillo J, Blanco J
Human vaccines 2024
CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits.
Koornneef A, Vanshylla K, Hardenberg G, Rutten L, Strokappe NM, Tolboom J, Vreugdenhil J, Boer KF, Perkasa A, Blokland S, Burger JA, Huang WC, Lovell JF, van Manen D, Sanders RW, Zahn RC, Schuitemaker H, Langedijk JPM, Wegmann F
Nature Communications 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
Moodie Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, Omar FL, Kee JJ, Bekker LG, Laher F, Naicker N, Jani I, Mgodi NM, Hunidzarira P, Sebe M, Miner MD, Polakowski L, Ramirez S, Nebergall M, Takuva S, Sikhosana L, Heptinstall J, Seaton KE, De Rosa S, Diazgranados CA, Koutsoukos M, Van Der Meeren O, Barnett SW, Kanesa-Thasan N, Kublin JG, Tomaras GD, McElrath MJ, Corey L, Mngadi K, Goepfert P
PLoS Medicine 2024
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial
Garrett N, Dintwe O, Monaco CL, Jones M, Seaton KE, Church EC, Grunenberg N, Hutter J, deCamp A, Huang Y, Lu H, Mann P, Robinson ST, Heptinstall J, Jensen RL, Pantaleo G, Ding S, Koutsoukos M, Hosseinipour MC, Van Der Meeren O, Gilbert PB, Ferrari G, Andersen-Nissen E, McElrath MJ, Tomaras GD, Gray GE, Corey L, Kublin JG
Journal of acquired immune deficiency syndromes (1999) 2024
SWIFT clustering analysis of intracellular cytokine staining flow cytometry data of the HVTN 105 vaccine trial reveals high frequencies of HIV-specific CD4+ T cell responses and associations with humoral responses
Mosmann TR, Rebhahn JA, De Rosa SC, Keefer MC, McElrath MJ, Rouphael NG, Pantaleo G, Gilbert PB, Corey L, Kobie JJ, Thakar J
Frontiers in immunology 2024
Safety and immunogenicity of a polyvalent DNA/polyvalent protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or co-administered in HIV-uninfected adults: a phase 1 randomised controlled trial
Frank I, Li SS, Grunenberg N, Overton ET, Robinson ST, Zheng H, Seaton KE, Heptinstall JR, Allen MA, Mayer KH, Culver DA, Keefer MC, Edupuganti S, Pensiero MN, Mehra VL, De Rosa SC, Morris DE, Wang S, Seaman MS, Montefiori DC, Ferrari G, Tomaras GD, Kublin JG, Corey L, Lu S
The Lancet HIV 2024
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)
Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L, Durand M, Rieux V, Diallo A, Lacabaratz C, Cardinaud S, Zurawski S, Zurawski G, Tomaras GD, Ding S, Centlivre M, Thiebaut R, Pantaleo G, Lelièvre JD, Richert L
eClinicalMedicine 2024
Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans
Basu M, Fucile C, Piepenbrink MS, Bunce CA, Man LX, Liesveld J, Rosenberg AF, Keefer MC, Kobie JJ
AIDS Research and Human Retroviruses 2023
Generating and measuring effective vaccine-elicited HIV-specific CD8+ T cell responses
Borgo GM, Rutishauser RL
Current Opinion in HIV and AIDS 2023
The Regulation of Nucleic Acid Vaccine Responses by the Microbiome
Johnson AM, Hager K, Alameh MG, Van P, Potchen N, Mayer-Blackwell K, Fiore-Gartland A, Minot S, Lin PJ, Tam YK, Weissman D, Kublin JG
2023
Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
Huang Y, Zhang Y, Seaton KE, De Rosa S, Heptinstall J, Carpp LN, Randhawa AK, McKinnon LR, McLaren P, Viegas E, Gray GE, Churchyard G, Buchbinder SP, Edupuganti S, Bekker LG, Keefer MC, Hosseinipour MC, Goepfert PA, Cohen KW, Williamson BD, McElrath MJ, Tomaras GD, Thakar J, Kobie JJ
EBioMedicine 2022
Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation
V Schijns, D Majhen, P van der Ley, A Thakur, A Summerfield, R Berisio, C Nativi, A Fernández-Tejada, C Alvarez-Dominguez, S Gizurarson, A Zamyatina, A Molinaro, C Rosano, Ž Jakopin, I Gursel, S McClean
Pharmaceutics 2021
Vaccine Design: Methods and Protocols, Volume 1. Vaccines for Human Diseases
S Thomas
2021
To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity
F Schlotthauer, J McGregor, HE Drummer
Viruses 2021
A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination
MM Lemke, MR McLean, CY Lee, E Lopez, ER Bozich, S Rerks-Ngarm, P Pitisuttithum, S Nitayaphan, S Kratochvil, BD Wines, PM Hogarth, SJ Kent, AW Chung, KB Arnold
Cell reports. Medicine 2021
DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses
H Li, S Wang, G Hu, L Zhang, S Liu, S Lu
Emerging Microbes & Infections 2021
Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
R Lassaunière, C Polacek, GJ Gram, A Frische, JL Tingstedt, M Krüger, BG Dorner, A Cook, R Brown, T Orekov, T Putmon-Taylor, TA Campbell, J Greenhouse, L Pessaint, H Andersen, MG Lewis, A Fomsgaard
npj Vaccines 2021
Robust antibody and cellular responses induced by DNA-only vaccination for HIV
Stephen DeRosa, Srilatha Edupuganti, Yunda Huang, Xue Han, Marnie Elizaga, Edith Swann, Laura Polakowski, Spyros A. Kalams, Michael C. Keefer, Janine Maenza, Yiwen Lu, Megan C. Wise, Jian Yan, Matthew P. Morrow, Amir S. Khan, Jean Boyer, Laurent M. Humeau, Scott White, Michael N. Pensiero, Niranjan Y. Sardesai, Mark Bagarazzi, David B. Weiner, Guido Ferrari, Georgia Tomaras, David Montefiori, Lawrence Corey, M. Juliana McElrath
JCI Insight 2020
Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1
MK Gorny
Human Vaccines & Immunotherapeutics 2020
Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
R Palli, KE Seaton, MS Piepenbrink, J Hural, PA Goepfert, F Laher, SP Buchbinder, G Churchyard, GE Gray, HL Robinson, Y Huang, H Janes, JJ Kobie, MC Keefer, GD Tomaras, J Thakar
Scientific Reports 2020
Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge
BK Felber, Z Lu, X Hu, A Valentin, M Rosati, CA Remmel, JA Weiner, MC Carpenter, K Faircloth, S Stanfield-Oakley, WB Williams, X Shen, GD Tomaras, CC LaBranche, D Montefiori, HV Trinh, M Rao, MS Alam, NA Vandergrift, KO Saunders, Y Wang, W Rountree, J Das, G Alter, SG Reed, PP Aye, F Schiro, B Pahar, JP Dufour, RS Veazey, PA Marx, DJ Venzon, GM Shaw, G Ferrari, ME Ackerman, BF Haynes, GN Pavlakis
Cell Reports 2020
Persistence of HIV-1 Env-Specific Plasmablast Lineages in Plasma Cells after Vaccination in Humans
M Basu, MS Piepenbrink, C Francois, F Roche, B Zheng, DA Spencer, AJ Hessell, CF Fucile, AF Rosenberg, CA Bunce, J Liesveld, MC Keefer, JJ Kobie
Reproduction 2020
Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
A Joachim, F Msafiri, S Onkar, P Munseri, S Aboud, EF Lyamuya, M Bakari, E Billings, ML Robb, B Wahren, FS Mhalu, E Sandström, M Rao, C Nilsson, G Biberfeld
Human vaccines 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
Z Moodie, SR Walsh, F Laher, L Maganga, ME Herce, S Naidoo, MC Hosseinipour, C Innes, LG Bekker, N Grunenberg, P Mann, C Yu, AC deCamp, MD Miner, NL Yates, J Heptinstall, NN Mkhize, O Dintwe, N Frahm, KW Cohen, M Allen, J Hutter, R Wagner, G Pantaleo, MJ McElrath, GD Tomaras, L Morris, DC Montefiori, E Andersen-Nissen, GE Gray, PB Gilbert, JG Kublin, P Pitisuttithum
PLoS Medicine 2020
Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases
Xu Z, Patel A, Tursi NJ, Zhu X, Muthumani K, Kulp DW, Weiner DB
2020
Simplified steps to heterologous prime-boost HIV vaccine development?
Nelson Michael
Journal of Clinical Investigation 2019

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 2 news outlets
Blogged by 2
Posted by 13 X users
On 1 Facebook pages
61 readers on Mendeley
See more details